Gotowa bibliografia na temat „Targeted alpha therapy”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Targeted alpha therapy”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Targeted alpha therapy"
HANAOKA, Hironari, i Tsutomu TAKEUCHI. "Interferon ^|^alpha;-targeted therapy". Japanese Journal of Clinical Immunology 36, nr 4 (2013): 181–88. http://dx.doi.org/10.2177/jsci.36.181.
Pełny tekst źródłaZalutsky, M. R., i G. Vaidyanathan. "383 TARGETED ALPHA THERAPY". Radiotherapy and Oncology 102 (marzec 2012): S195. http://dx.doi.org/10.1016/s0167-8140(12)70332-8.
Pełny tekst źródłaKozempel, Jan, i Martin Vlk. "Nanoconstructs in Targeted Alpha-Therapy". Recent Patents on Nanomedicine 4, nr 2 (11.03.2015): 71–76. http://dx.doi.org/10.2174/1877912305666150102000549.
Pełny tekst źródłaMorgenstern, Alfred, Frank Bruchertseifer i Christos Apostolidis. "Targeted Alpha Therapy with 213Bi". Current Radiopharmaceuticalse 4, nr 4 (1.10.2011): 295–305. http://dx.doi.org/10.2174/1874471011104040295.
Pełny tekst źródłaMajkowska-Pilip, Agnieszka, Weronika Gawęda, Kinga Żelechowska-Matysiak, Kamil Wawrowicz i Aleksander Bilewicz. "Nanoparticles in Targeted Alpha Therapy". Nanomaterials 10, nr 7 (13.07.2020): 1366. http://dx.doi.org/10.3390/nano10071366.
Pełny tekst źródłaVaidyanathan, Ganesan, i Michael R. Zalutsky. "Targeted therapy using alpha emitters". Physics in Medicine and Biology 41, nr 10 (1.10.1996): 1915–31. http://dx.doi.org/10.1088/0031-9155/41/10/005.
Pełny tekst źródłaAllen, Barry J., Chand Raja, Syed Rizvi, Yong Li, Wendy Tsui, David Zhang, Emma Song i in. "Targeted alpha therapy for cancer". Physics in Medicine and Biology 49, nr 16 (31.07.2004): 3703–12. http://dx.doi.org/10.1088/0031-9155/49/16/016.
Pełny tekst źródłaSgouros, George. "Alpha-particles for targeted therapy". Advanced Drug Delivery Reviews 60, nr 12 (wrzesień 2008): 1402–6. http://dx.doi.org/10.1016/j.addr.2008.04.007.
Pełny tekst źródłaMorgenstern, A., K. Abbas, F. Bruchertseifer i C. Apostolidis. "Production of Alpha Emitters for Targeted Alpha Therapy". Current Radiopharmaceuticalse 1, nr 3 (1.09.2008): 135–43. http://dx.doi.org/10.2174/1874471010801030135.
Pełny tekst źródłaJ. Allen, Barry. "Future Prospects for Targeted Alpha Therapy". Current Radiopharmaceuticalse 4, nr 4 (1.10.2011): 336–42. http://dx.doi.org/10.2174/1874471011104040336.
Pełny tekst źródłaRozprawy doktorskie na temat "Targeted alpha therapy"
Song, Emma Yanjun Clinical School St George Hospital Faculty of Medicine UNSW. "Targeted alpha therapy for epithelial ovarian cancer". Awarded by:University of New South Wales. Clinical School - St George Hospital, 2007. http://handle.unsw.edu.au/1959.4/40874.
Pełny tekst źródłaAndrews, Shannon. "FOLATE CONJUGATED DENDRIMERS FOR TARGETED ANTICANCER THERAPY". VCU Scholars Compass, 2014. http://scholarscompass.vcu.edu/etd/3497.
Pełny tekst źródłaPashaeinejad, Masoumeh Physics Faculty of Science UNSW. "Targeted alpha-therapy:cell survival determination in melanoma tumours using Monte Carlo calculations". Awarded by:University of New South Wales. Physics, 2006. http://handle.unsw.edu.au/1959.4/23996.
Pełny tekst źródłaToro-Gonzalez, Miguel. "LANTHANIDE-BASED CORE-SHELL NANOPARTICLES AS MULTIFUNCTIONAL PLATFORMS FOR TARGETED RADIONUCLIDE THERAPY AND MULTIMODAL MOLECULAR IMAGING". VCU Scholars Compass, 2018. https://scholarscompass.vcu.edu/etd/5647.
Pełny tekst źródłaPetitprin, Aurélie. "Le RAFT-RGD radiomarqué avec un émetteur °- comme nouvel agent de radiothérapie interne vectorisée". Thesis, Grenoble, 2013. http://www.theses.fr/2013GRENS002/document.
Pełny tekst źródłaΒ- emitters radiolabeled RAFT-RGD as new agents for internal targeted radiotherapy. The αvβ3 integrin is known to play an important role in tumor-induced angiogenesis, tumor proliferation, survival and metastasis. Because of its overexpression on neoendothelial cells such as those present in growing tumors, as well as on tumor cells of various origins, αvβ3 integrin is an attractive molecular target for diagnosis and therapy of the rapidly growing and metastatic tumors. A tetrameric RGD-based peptide, regioselectively addressable functionalized template-(cyclo-[RGDfK])4 (RAFT-RGD), specifically targets integrin αvβ3 in vitro and in vivo. RAFT-RGD has been used for tumor imaging and drug targeting. This study is the first to evaluate the therapeutic potential of the β- emitters radiolabeled tetrameric RGD peptide RAFT-RGD in a Nude mouse model of αvβ3-expressing tumors. An injection of 37 MBq of 90Y-RAFT-RGD or 177Lu-RAFT-RGD in mice with αvβ3-positive tumors caused a significant growth delay as compared with mice treated with 37 MBq of 90Y-RAFT-RAD or 177Lu-RAFT-RAD or untreated mice. In comparison, an injection of 30 MBq of 90Y-RAFT-RGD had no efficacy for the treatment of αvβ3-negative tumors. 90Y-RAFT-RGD and 177Lu-RAFT-RGD are potent αvβ3-expressing tumor targeting agents for internal targeted radiotherapy. Keys words : integrin αvβ3, RAFT-RGD, tumour targeting, internal targeted radiotherapy
Doligalski, Michael Lawrence. "Design and Development of Peptidomimetic Ligands for Targeting Radiopharmaceuticals, Imaging Probes, and Immunotherapeutics in Oncologic Disease". Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6492.
Pełny tekst źródłaKostova, Vesela. "Shiga toxin targeted strategy for chemotherapy and cancer immunotherapy application using copper-free « Click » chemistry". Thesis, Sorbonne Paris Cité, 2015. http://www.theses.fr/2015USPCB144.
Pełny tekst źródłaRecently targeted therapies appeared as attractive alternatives to classical antitumoral treatments. The approach, developed on the concept of targeting drug to cancer cells, aims to spear normal tissues and decrease the side effects. This doctoral dissertation focuses on developing new anticancer targeted treatments in the field of chemotherapy and cancer immunotherapy by exploiting an original targeting moiety, the B subunit of Shiga toxin (STxB). Its specific properties, such as, recognition with its receptor Gb3 overexpressed in cancer cells or in antigen-presenting cells, its unconventional intracellular trafficking, guided the choice of this protein as targeting carrier. This project is based in the use of copper-free Huisgen [3+2] cycloaddition as a coupling method, which led to successful preparation of various conjugates for their respective applications. The concept was first validated by STxB-biotin conjugate. The high yield of the reaction and the compatibility between the targeting carrier and the chemical ligation promoted the design of conjugates for chemotherapy and immunotherapy. Two therapeutical optimizations of previously developed strategy in STxB drug targeting delivery were investigated: synthesis of multivalent drug-conjugates and synthesis of conjugates containing a highly potent anticancer agent. Both approaches exploited three anticancer agents: SN38, Doxorubicin and Monomethyl auristatin F. The disulfide spacer, combined with various self-immolative systems, insured drug release. Two cytotoxic conjugates STxB–doxorubicin (STxB-Doxo) and STxB-monomethyl auristatin F (STxB-MMAF) were obtained in very high yield and demonstrated strong tumor inhibition activity in the nanomolar range on Gb3-positive cells. Based on the results the STxB-MMAF conjugate was investigated on a mouse model. The project aimed also to develop STxB bioconjugates for vaccine applications. Previous studies used B subunit as a targeting carrier coupled to an antigenic protein in order to induce a more potent immune response against cancer. The conjugates were prepared using a commercial linker, requiring modifying the antigen at first place, or by oxime ligation, where slightly acidic conditions promoted the coupling. Thus, the work presented herein proposed an alternative ligation via copper-free click chemistry especially for more sensitive antigenic proteins. Various types of conjugates were synthesised and investigated for their immune stimulation properties. The STxB targeting strategy was also applied to the development of a new vaccine based on coupling the targeting carrier to alpha-GalCer, one of the most potent immune stimulating agents known. The work focused on the synthesis of functionalised alpha-Galcer with an azide handle
Kannengießer, Stefanie [Verfasser], i Thomas [Akademischer Betreuer] Fanghänel. "Optimization of the Synthesis of Ac-225-labelled DOTA-Radioimmunoconjugates for Targeted Alpha Therapy, based on Investigations on the Complexation of Trivalent Actinides by DOTA / Stefanie Kannengießer ; Betreuer: Thomas Fanghänel". Heidelberg : Universitätsbibliothek Heidelberg, 2013. http://d-nb.info/1177148838/34.
Pełny tekst źródłaGruntman, Alisha. "A Translational Pathway for Recombinant Adeno-Associated Virus Human Gene Therapy: From Target Identification and Animal Modeling of the Disease to Non-Human Primate and Human Studies". eScholarship@UMMS, 2011. http://escholarship.umassmed.edu/gsbs_diss/882.
Pełny tekst źródłaGruntman, Alisha. "A Translational Pathway for Recombinant Adeno-Associated Virus Human Gene Therapy: From Target Identification and Animal Modeling of the Disease to Non-Human Primate and Human Studies". eScholarship@UMMS, 2016. https://escholarship.umassmed.edu/gsbs_diss/882.
Pełny tekst źródłaKsiążki na temat "Targeted alpha therapy"
Chŏn, Yang-suk. Chongyang ŭi sansŏnghwa e ŭihan HIF-1[alpha] kwabarhyŏn kijŏn kyumyŏng kwa saeroun hangam chʻiryo tʻaget ŭi palgul =: Mechanism of HIF-1[alpha] overexpression in acidified tumor and novel target for anticancer therapy. [Seoul]: Pogŏn Pokchibu, 2007.
Znajdź pełny tekst źródłaRai, Samarpit, Zachariah G. Goldsmith, Michael E. Lipkin i Glenn M. Preminger. Ureteric stones. Redaktor John Reynard. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0026.
Pełny tekst źródłaCassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, Gareth Morris-Stiff i Madhumita Bhattacharyya. Gynaecological cancers. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0020_update_001.
Pełny tekst źródłaDe Backer, Daniel, i Patrick Biston. Vasopressors in critical illness. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0034.
Pełny tekst źródłaCzęści książek na temat "Targeted alpha therapy"
Mastren, Tara. "Targeted Alpha Therapy". W Rare Earth Elements and Actinides: Progress in Computational Science Applications, 277–83. Washington, DC: American Chemical Society, 2021. http://dx.doi.org/10.1021/bk-2021-1388.ch013.
Pełny tekst źródłaSeidl, Christof, i Reingard Senekowitsch-Schmidtke. "Targeted Alpha Particle Therapy of Peritoneal Carcinomas". W Therapeutic Nuclear Medicine, 557–67. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/174_2012_678.
Pełny tekst źródłaChaudhri, M. Anwar, M. Nasir Chaudhri, Qamar Nadeem i Qaiser Jabbar. "Production of Ac-225 with Cyclotrons for Generating Bi-213 for Targeted Alpha Therapy". W IFMBE Proceedings, 686–87. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-642-03474-9_193.
Pełny tekst źródłaZheng, Yifan, Yoonsuk Huh, Qianqian Su, Jiaming Wang, Yunduan Lin, Kai Vetter i Youngho Seo. "Collimatorless Scintigraphy for Imaging Extremely Low Activity Targeted Alpha Therapy (TAT) with Weighted Robust Least Squares (WRLS)". W Medical Image Computing and Computer Assisted Intervention – MICCAI 2020, 803–11. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-59728-3_78.
Pełny tekst źródłaSchultz, Michael K., Jean-Pierre Pouget, Frank Wuest, Bryce Nelson, Jan Andersson, Sarah Cheal, Mengshi Li i in. "Radiobiology of Targeted Alpha Therapy". W Nuclear Medicine and Molecular Imaging, 380–403. Elsevier, 2022. http://dx.doi.org/10.1016/b978-0-12-822960-6.00093-4.
Pełny tekst źródłaChatterjee, Sayandev, Kenneth R. Czerwinski, Hilary A. Fitzgerald, Andrew L. Lakes, Zuolei Liao, Russell C. Ludwig, Katie M. McBride i Vladislav P. Vlasenko. "Delivery of radiopharmaceuticals and theranostic agents: targeted alpha therapy". W Novel Platforms for Drug Delivery Applications, 349–404. Elsevier, 2023. http://dx.doi.org/10.1016/b978-0-323-91376-8.00012-4.
Pełny tekst źródłaAbbasi, Akbar, Hesham M.H. Zakaly i Fatemeh Mirekhtiary. "Radium-223 and Actinium-225 α-Emitter Radiopharmaceuticals in Treatment of Metastatic Castration-Resistant Prostate Cancer". W Radiopharmaceuticals - Current Research for Better Diagnosis and Therapy. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.99756.
Pełny tekst źródła"Current Status of PSMA Targeted Alpha Therapy in Prostate Cancer Patients". W The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo, redaktorzy Thabo Lengana i Mike Sathekge, 255–64. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9781681088655122010023.
Pełny tekst źródła"Bone Targeted Radionuclide Therapy in Russia From Beta- to Alpha- Emitters". W The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo, redaktorzy N. G. Seleva, V. V. Krylov i T. Yu Kochetova, 368–83. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9781681088655122010034.
Pełny tekst źródłaConstanzo, Julie, Clara Diaz Garcia-Prada i Jean-Pierre Pouget. "Clonogenic assay to measure bystander cytotoxicity of targeted alpha-particle therapy". W Methods in Cell Biology. Elsevier, 2022. http://dx.doi.org/10.1016/bs.mcb.2022.08.005.
Pełny tekst źródłaStreszczenia konferencji na temat "Targeted alpha therapy"
Tafreshi, Narges K., Nella C. Delva, Christopher J. Tichacek, Michael L. Doligalski, Darpan N. Pandya, Nikunj B. Bhatt, HyunJoo Kil i in. "Abstract 5198: Targeted alpha particle therapy for uveal melanoma". W Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-5198.
Pełny tekst źródłaHasegawa, S., i HK Li. "PO-110 Targeted alpha-therapy for gastric cancer metastasized to liver in mice". W Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.635.
Pełny tekst źródłaSchmidtlein, Charles Ross, Matthew K. Maroun, Andrzej Krol, Howard Gifford, Lisa Bodei, Joseph O'Donoghue, Ida Häggström i Yuesheng Xu. "A deblurring/denoising corrected scintigraphic planar image reconstruction model for targeted alpha therapy". W Biomedical Applications in Molecular, Structural, and Functional Imaging, redaktorzy Barjor S. Gimi i Andrzej Krol. SPIE, 2021. http://dx.doi.org/10.1117/12.2584736.
Pełny tekst źródłaBruchertseifer, F., L. Krolicki, J. Kunikowska, H. Koziara, B. Krolicki, M. Jakucinski, D. Pawlak, A. Apostolidis i A. Morgenstern. "Targeted alpha therapy of recurrent glia tumors: clinical experience with 225 Ac-Substance-P". W NuklearMedizin 2020. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1708255.
Pełny tekst źródłaTworowska, Izabela, Ebrahim S. Delpassand, Julien Torgue, Farah Shanoon, Jason Hurt i Rodolfo Nunez. "Abstract CT159: First-in-human dose escalation of AlphaMedixTMfor targeted alpha-emitter therapy of neuroendocrine tumors". W Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-ct159.
Pełny tekst źródłaEriksson, Sophie E., Erika Elgström, Sture Lindegren i Tom Bäck. "Abstract 834: Formation of DNA double-strand breaks in colon tumors after targeted alpha therapy with211At-mAb". W Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-834.
Pełny tekst źródłaHasegawa, Sumitaka, i Huizi Keiko Li. "Abstract 5343: Experimental targeted alpha-particle therapy against liver metastasis of HER2-positive gastric cancer in mice". W Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-5343.
Pełny tekst źródłaRold, Tammy L., Nkemakonam C. Okoye, Thomas P. Quinn i Timothy J. Hoffman. "Abstract 5344: Treatment efficacy of212Pb-RM2 targeted alpha therapy in human prostate cancer cell lines: Anin vitroinvestigation". W Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-5344.
Pełny tekst źródłaLabadie, Kevin P., Donald K. Hamlin, Aimee Kenoyer, Sara K. Daniel, Alan F. Utria, Andrew D. Ludwig, Heidi L. Kenerson i in. "Abstract 928: Glypican-3 targeted thorium-227 alpha therapy reduces tumor burden in an orthotopic xenograft model of hepatocellular carcinoma". W Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-928.
Pełny tekst źródłaHu, Meiduo, John Forbes, Ryan Simms, Yaryna Storozhuk, Eric Burak i John Valliant. "Abstract LB130: Combination of IGF-1R targeted alpha therapy with Olaparib results in synergistic efficacy against colorectal and lung cancer xenografts". W Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-lb130.
Pełny tekst źródłaRaporty organizacyjne na temat "Targeted alpha therapy"
Sgouros, George. Therapy of Ovarian Carcinoma by Targeted Delivery of Alpha-Particles Using Immunoliposomes Capable of Retaining Alpha-Emitting Daughters. Fort Belvoir, VA: Defense Technical Information Center, październik 2005. http://dx.doi.org/10.21236/ada448269.
Pełny tekst źródłaSgouros, George. Therapy of Ovarian Carcinoma by Targeted Delivery of Alpha-Particles Using Immunoliposomes Capable of Retaining Alpha-Emitting Daughters. Fort Belvoir, VA: Defense Technical Information Center, październik 2004. http://dx.doi.org/10.21236/ada431313.
Pełny tekst źródłaMa, Jiao, Lanyin Li, Taiping Liao, Weidong Gong i Chunyin Zhang. Efficacy and safety of 225Ac-PSMA-617-targeted alpha therapy in metastatic castration-resistant prostate cancer:a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, wrzesień 2021. http://dx.doi.org/10.37766/inplasy2021.9.0103.
Pełny tekst źródła